Todd Agnew
Optometrist · Dallas, TXNPI 1285660654
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 147 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Among optometrist clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $35.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- AbbVie$713
- Novartis$568
- Bausch & Lomb Americas Inc.$516
- Johnson & Johnson Surgical Vision, Inc.$395
- Biotissue Holdings Inc.$297
- plus $2K from 15 others
Across 22 payments — averaging $1202.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$26K
- Rxsight Inc$16
What the payments were for
- Speaking & faculty fees$260%
- Food & beverage$5,183100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 33 | $1,218 |
| AbbVie(2 entities) | 24 | $713 |
| Novartis | 19 | $568 |
| Bausch & Lomb Americas Inc. | 13 | $516 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $395 |
| Biotissue Holdings Inc. | 4 | $297 |
| Tarsus Pharmaceuticals, Inc. | 7 | $253 |
| Harrow Eye, LLC | 5 | $192 |
| Rxsight Inc | 5 | $186 |
| Oyster Point Pharma, Inc. | 3 | $163 |
| Alcon Research LLC | 1 | $134 |
| Johnson & Johnson Vision Care, Inc. | 4 | $115 |
| Sun Pharmaceutical Industries Inc. | 6 | $108 |
| Aerie Pharmaceuticals, Inc. | 5 | $95 |
| Glaukos Corporation | 2 | $63 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $52 |
| Thea Pharma Inc. | 2 | $38 |
| Amgen(2 entities) | 2 | $36 |
| Astellas Pharma US Inc | 1 | $32 |
| Shire North American Group Inc | 1 | $21 |
| Akorn, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$269
- AmnioGraft$269
- DAILIES$252
- INFUSE$168
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$131
- TYRVAYA$129
- XDEMVY$128
- MIEBO$125
- XIIDRA$123
- Tecnis Symfony IOL$122
- Tecnis Multifocal Family of 1-piece IOLS$122
- Tecnis Toric 1-piece IOL$122
- VEVYE$120
- Wavelight Sightmap$116
- RESTASIS$114
- LUMIGAN$112
How this compares
$5,208 in reported general payments places this provider in the 90th percentile of 4,315 optometrist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 57 | $64,620 |
| RestasisCyclosporine | 47 | $61,820 |
| LumiganBimatoprost | 94 | $54,671 |
| MieboPerfluorohexyloctane/Pf | 36 | $36,421 |
| VyzultaLatanoprostene Bunod | 23 | $12,398 |
| Loteprednol Etabonate | 55 | $6,778 |
| Cyclosporine | 11 | $6,742 |
| Alphagan PBrimonidine Tartrate | 11 | $6,085 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 69 | $3,288 |
| Latanoprost | 220 | $2,406 |
| Prednisolone Acetate | 72 | $1,726 |
| Brimonidine Tartrate | 40 | $985 |
| Fluorometholone | 14 | $930 |
| Doxycycline Hyclate | 25 | $667 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 63 | $527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Alphagan P | $713 | $122,576152 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $516 | $113,439116 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $52 | $6,77855 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,315 optometrist providers in Texas.
Other optometrist in Dallas
- Laurence ThomasDallas$103K
- Kenneth UzickDallas$61K
- Lilia FloresDallas$22K
- Derek CunninghamAustin$940K
- Claudio LagunasHouston$644K
- Ashley Wallace-TuckerHouston$547K
- Luis RojasMcKinney$309K
- Emile FadelAustin$225K
- Bridgitte LeeHouston$222K
- Phillip BrunsonHouston$214K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.